funded by Amgen (Europe) GmbH. Jean-Jacques Body has received speaker and consulting fees from Amgen; Francesca Gatta is an employee of Amgen; Erwin De Cock and Persefoni Kritikou were employees of UBC
Background Rituximab is a standard treatment for non-Hodgkin lymphoma. The SABRINA trial (NCT01200758) showed that a subcutaneous (SC) rituximab formulation did not compromise efficacy or safety compared with intravenous (IV) infusion. We aimed to quantify active healthcare professional (HCP) time and patient chair time for rituximab SC and IV, including potential time savings. ...
was carried out with financial support from Cook Medical. Marc Sapoval and Pierre Julia received an honorary fee for the work involved in expert consultation and manuscript development. Erwin De Cock
of the findings. Erwin De Cock reviewed the manuscript and assisted in data collection and data analysis. Ann-Christin Mrk reviewed the manuscript and participated in the design and implementation of